Merck China CEO Michel Vounatsos And Emerging Markets R&D Senior VP RuiPing Dong On Provincial Management: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Executive Summary
Merck & Co. Inc. CEO Kenneth Frazier was the keynote speaker at the China Healthcare Investment Conference in Beijing March 23, stressing that his trip highlighted the place the Chinese market holds for the company's growth. After the conference, Merck, Sharpe and Dohme China President Michel Vounatsos and Merck Research Laboratory Senior VP for Emerging Markets RuiPing Dong spoke with PharmAsia News about navigating China's provincial markets and fitting China into a global R&D strategy.
You may also be interested in...
Merck And Simcere Trial Partnership In China: Two Different Cultures But One Common Goal
NANJING, China - A few weeks after Merck & Co.'s China affiliate MSD and one of China's leading drug makers Simcere Pharmaceutical Group announced a new joint venture to expand access to critical lifestyle drugs across China, the two companies unveiled more details to their innovative partnership
Merck And Simcere Trial Partnership In China: Two Different Cultures But One Common Goal
NANJING, China - A few weeks after Merck & Co.'s China affiliate MSD and one of China's leading drug makers Simcere Pharmaceutical Group announced a new joint venture to expand access to critical lifestyle drugs across China, the two companies unveiled more details to their innovative partnership
Merck Invests In China Oncology Start-Ip BeiGene
On the second Monday of each month, "The Pink Sheet" provides exclusive news and commentary on the Asia biopharma market from the editors of its affiliated online publication, PharmAsia News. Register at http://pharmasianews.elsevierbi.com/PAN_Trial_LP.html for a free trial.